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Abstract
Background:  Patients with cancer must make frequent visits to the clinic not only for
chemotherapy but also for the management of treatment-related adverse effects. Neutropenia, the
most common dose-limiting toxicity of myelosuppressive chemotherapy, has substantial clinical and
economic consequences. Colony-stimulating factors such as filgrastim and pegfilgrastim can reduce
the incidence of neutropenia, but the clinic visits for these treatments can disrupt patients' routines
and activities.
Methods: We surveyed patients to assess how clinic visits for treatment with chemotherapy and
the management of neutropenia affect their time and activities.
Results: The mean amounts of time affected by these visits ranged from approximately 109 hours
(hospitalization for neutropenia) and 8 hours (physician and chemotherapy) to less than 3 hours
(laboratory and treatment with filgrastim or pegfilgrastim). The visits for filgrastim or pegfilgrastim
were comparable in length, but treatment with filgrastim requires several visits per chemotherapy
cycle and treatment with pegfilgrastim requires only 1 visit.
Conclusions: This study provides useful information for future modelling of additional factors
such as disease status and chemotherapy schedule and provides information that should be
considered in managing chemotherapy-induced neutropenia.
Background
Cancer is a devastating disease that affects patients' quality
of life. The treatment of cancer also causes problems for
patients, such as nausea and vomiting, anemia, and neu-
tropenia [1-6]. Moreover, a diagnosis of cancer necessi-
tates a large number of medical visits for monitoring the
disease, treating it, and providing supportive care.
The treatment of cancer may require that patients visit an
outpatient clinic numerous times over a course of months
or years. Those patients who have employment often have
to take time off work for long periods to be treated and
have to shift many of their activities and responsibilities
because of the time required for treatment. Patients spend
time preparing, travelling to the clinic, waiting at the
clinic, and travelling from the clinic. These visits affect
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their normal life activities both in the time taken away
from those activities and in their associated costs, such as
lost work time. In addition, there can be logistical chal-
lenges in transportation and living arrangements and dis-
ruptions of work and daily living. The stress associated
with these visits can also affect their psychological
outlook.
The number of medical visits that are necessary with
chemotherapy treatment depends on many factors,
including the type and extent of the disease and the sched-
ule of the chemotherapy. One of the factors that can
greatly affect the number of visits is chemotherapy-
induced neutropenia. Chemotherapy-induced neutrope-
nia is the most common dose-limiting toxicity of myelo-
suppressive chemotherapy, and it has several economic
and clinical consequences [7]. Neutropenia also puts
patients at high risk for infection, and it can be life-threat-
ening [7]. If not managed properly, neutropenia can result
in a large number of medical visits for monitoring the
neutrophil counts, outpatient intravenous antibiotics,
physician and nurse visits, and hospitalization [8].
Supportive therapies such as colony-stimulating factors
(CSFs) can reduce the incidence of chemotherapy-
induced neutropenia [5]. The CSFs filgrastim and pegfil-
grastim are indicated to decrease the incidence of infec-
tion, as manifested by febrile neutropenia, in patients
with nonmyeloid malignancies treated with myelosup-
pressive anticancer drugs [9,10]. Both of these agents are
effective in reducing the risks and incidence of neutrope-
nia and its complications, but they too can affect patients'
quality of life, by requiring additional medical visits.
Treatment with filgrastim can require up to 10 or more
daily injections per chemotherapy cycle for its full benefits
to be obtained; pegfilgrastim, however, is given only once
per cycle [11]. The clinic visits that are necessary for man-
aging chemotherapy-induced neutropenia with CSFs can
also disrupt patients' lives and create stress.
The purpose of this study was to determine the amounts
of time required for medical visits in treatment with
chemotherapy and to better understand the implications
of the strategies for managing chemotherapy-induced
neutropenia.
Methods
Design
All study procedures were approved by the Western Insti-
tutional Review Board. The study design was a 20-site sin-
gle-time-point survey of patients with cancer in
community-based oncology practices. Patients were
selected in a nonrandom fashion according to the inclu-
sion criteria.
Patients
Patients were enrolled between May 2003 and July 2003.
They were required to be at least 18 years old and must
have been treated with primary prophylaxis with either fil-
grastim or pegfilgrastim 1 month before enrollment. Writ-
ten informed consent was obtained from all patients, and
they were not given any monetary incentives or compen-
sations for participating in the study.
Procedures
Patients' disease status and treatment history were ascer-
tained by chart review. Patients were administered the
Patient Impact Survey, a semistructured interview created
for the study by the primary author, which identified
activities that were altered because of the types of medical
visits that are typical with a 21-day chemotherapy cycle.
See additional data file 1, Doctor and Chemo Survey.pdf,
for a sample survey page. Patients were interviewed about
13 kinds of caregiver interactions; the results focus on data
from 8 of those events, listed in Table 1. Patients were
asked to list the activities that were affected by each visit
and to estimate the time associated with them. The total
amount of time affected included that for activities that
would have normally been done during the time of the
visit and the time before and after the visit (eg, travel to
and from the medical office, time off work, rescheduled
social activities). Data on the most recent medical visit of
each type were collected.
Table 1: Medical visits
Physician and chemotherapy visit
Physician visit
Nurse practitioner visit
Laboratory visit
Intravenous antibiotics
Filgrastim visit
Pegfilgrastim visit
Neutropenia-related hospitalizationBMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/22
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Results
Patient demographics
A total of 189 patients participated. Their demographics
are given in Table 2. Most of the patients were women and
of white ethnicity; their mean age was 60 years; and
35.6% were employed at the time.
Effects on patients
The total amounts of time that were affected by medical
visits are shown in Figure 1. These times consist of the
time before, during, and after the medical visit. Patients
reported the time spent at the clinic, the time spent travel-
ling to and from the clinic, and the time affected by work
or social activities that were altered before and after the
visit. Hospitalization for neutropenia-related complica-
tions accounted for the greatest amount of patient time,
followed by a visit to the clinic to see the physician and be
treated with chemotherapy. It should be noted that visits
in which the procedures are relatively brief, such as labo-
ratory visits and visits to be treated with filgrastim and
pegfilgrastim, also accounted for substantial amounts of
time. The values reported are for single visits, and it
should also be noted that a complete course of treatment
with intravenous antibiotics or filgrastim requires several
visits and the total amount of time for such treatment
would be much greater.
Table 2: Patient demographics (N = 189)
Age, y, mean (SD) 59.9 (13.4)
Sex
Male 51 (27%)
Female 138 (73%)
Ethnicity
White 157 (83.5%)
Hispanic 8 (4%)
Black 19 (10.1%)
Asian or Pacific Island 1 (0.5%)
Native American or Alaska Native 1 (0.5%)
Other 2 (1.1%)
Marital status
Single 22 (11.6%)
Separated 1 (0.5%)
Divorced 20 (10.6%)
Widowed 23 (12.2%)
Remarried 1 (0.5%)
Married 122 (64.5%)
Work status
Currently working 67 (35.6%)
Unemployed, looking for work 5 (2.7%)
Homemaker 28 (14.9%)
Retired 87 (46.3%)
Student 1 (0.5%)
Education
Less than high school 2 (1%)
Some high school 22 (11.6%)
High school diploma 53 (28%)
Some college 62 (32.8%)
College degree 29 (15%)
Some graduate school 5 (2.6%)
Graduate degree 16 (8.5%)
Annual household income, US$
<15,000 27 (14.3%)
15,000–30,000 35 (18.5%)
30,000–50,000 39 (21%)
50,000–75,000 24 (13%)
75,000–100,000 15 (7.9%)
100,000–150,000 9 (5%)
>150,000 10 (5.3%)
Prefer not to say 30 (15.9%)BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/22
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The numbers of life activities that were affected by the vis-
its are shown in Figure 2. The activities most frequently
cited by patients were work, community activities, family
obligations, and daily responsibilities such as housework
and family care. All visits affected at least 1 life activity. As
would be expected, neutropenia-related hospitalizations
and physician and chemotherapy visits affected the great-
est number of life activities. And, as noted above, a course
of treatment with intravenous antibiotics or filgrastim
would require several visits and would thus be expected to
affect a greater number of life activities.
Discussion
This study shows that, from the point of view of the
patient, there is no such thing as a short clinic visit. As
expected, patient time was affected most by neutropenia-
related hospitalizations, but even visits for relatively sim-
ple procedures, such as laboratory draws, take a lot of
time. Clinic visits for these purposes cause patients to
deviate from their normal activities and prevent them
from pursuing their normal life activities.
This study looked at patient time and life activities that
were affected before and after the actual visit, as well as the
time of the visit itself. Lindley and colleagues also
reported that patient time was affected after a visit in addi-
tion to the visit itself [12]. For example, rescheduling trips
or extending work activities can result in a large amount
of time being affected by medical visits. Meehan and col-
leagues found that the average time spent travelling to a
clinic was 40 minutes [13]. The time spent travelling for
treatment can be a potential barrier to patients' seeking
Patient time affected by medical visits Figure 1
Patient time affected by medical visits Patient times affected by medical visits, with the point and bar indicating the mean 
and standard deviation, the vertical line indicating the median, the limits of the box indicating the 25th and 75th percentiles, and 
the extensions indicating the range. Not all types of visits were reported at all sites (N = 20) or by all patients (N = 189).
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treatment and keeping their medical appointments.
Patients must have reliable transportation [14], which can
be difficult if they have limited access to transportation or
if long distances are involved [15,16]. Transportation can
be especially problematic if the patient cannot drive, does
not have a car, or uses a wheelchair [14]. Public transpor-
tation is often unreliable and time-consuming. Patients
also often make alternative living arrangements so that
they can have better access to a caregiver or to the clinic
[14]. The effects of travelling to the clinic can be so great
that impaired access to transportation may cause patients
to forgo treatment [17,18].
In addition to the logistical inconveniences and economic
hardships of travel [16], it can be another source of stress
and can have negative psychological effects on patients
[19]. This stress could even affect their willingness to
undergo further treatment [12]. Worrying about going to
the clinic decreases patients' energy levels and functional-
ity for daily activities. Patients' stress, anxiety, and depres-
sion may increase, especially if they do not understand
why they must visit the clinic numerous times. Managing
this stress can improve patients' well-being [20].
In addition to the costs associated with travelling to the
clinic [15,16], the costs associated with lost work time
may be an economic burden for patients [14]. Overnight
accommodations may be required, and out-of-pocket
expenses can be substantial. Patients often have little or
no insurance coverage for out-of-pocket or incidental
expenses such as lodging, gas, and meals [14,21,22]. Mee-
han and colleagues reported that not only were clinic vis-
its time-consuming and inconvenient for both patients
and their caregivers, but they also generated no reimburs-
able costs [13]. Other studies have also found that trans-
portation is the largest out-of-pocket expense for
treatment, followed by meals [21,23].
Life activities affected by medical visits Figure 2
Life activities affected by medical visits Life activities affected by medical visits, with the point and bar indicating the mean 
and standard deviation, the vertical line indicating the median, the limits of the box indicating the 25th and 75th percentiles, and 
the extensions indicating the range. Not all types of activities were reported at all sites (N = 20) or by all patients (N = 189).
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In addition to time, each clinic visit affects several life
activities, which results in patients' changing, postponing,
or cancelling those activities. At least 1 life activity was
affected by each type of medical visit. As expected, the
medical visit that accounted for the most time, neutrope-
nia-related hospitalization, also affected more life activi-
ties than the other types of visits.
The time that was required for a single visit for treatment
with filgrastim was the same as that for a visit for treat-
ment with pegfilgrastim, but treatment with filgrastim
requires several daily visits during a cycle of
chemotherapy and treatment with pegfilgrastim requires
only 1 visit. If patients are given 10 daily injections of fil-
grastim, which may be necessary for their ANC to reach
the recommended 10 × 109/L [9], the time required would
be 24 hours, whereas equivalent treatment with pegfil-
grastim would take less than 3 hours.
Patient care can be optimized by reducing the number of
clinic visits. Nurses play a central role in minimizing the
disruptions that treatment has on the lives of patients and
their families and caregivers, and patients often perceive
nurses as being a liaison between themselves and their
physicians [5]. Nurses can educate and instruct patients
on how to manage their symptoms, such as what symp-
toms to report and how and when to take their tempera-
ture. Implementing protocols and guidelines can improve
the management of neutropenia and can help nurses con-
duct patient assessments more efficiently [24,25]. Tele-
phone triage in particular can be effective, convenient,
and practical, by helping determine which patients should
be seen frequently and which patients can be managed by
telephone [26].
The choice of the treatment can also help reduce the
number of clinic visits. Moore and colleagues reported
that the amount of time actually spent at the clinic may be
inconsequential, because patients still have to interrupt
their routines to go to the clinic [14]. The CSF used to
manage neutropenia can be important and can affect the
number of clinic visits and amount of patient time.
Decreasing the number of clinic visits can have a positive
effect on patients by improving their functional [2,3,21],
social [2,21], and financial well-being [14,21,23], in addi-
tion to decreasing their emotional stress [1,14,27]. The
greater convenience of fewer clinic visits could also
increase patient adherence and lessen the likelihood that
patients might put themselves at greater risk for neutrope-
nia by not going to the clinic for their treatment.
Conclusions
This study provides new data on how medical visits affect
patients. It is clear that treatment with chemotherapy – as
well as the management of adverse events – involves a
great number of medical visits and that these visits have
substantial effects on patient time and activities. The study
is based solely on patient self-reports, however, and the
extent to which patients can accurately recall this type of
information is not certain. Future studies might use other
methods, such as prospective observation or patient dia-
ries, to confirm and extend these findings.
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